Cathie Wood’s ARK sells Palantir and Roku, buys more Twist Bioscience

Cathie Wood’s ARK ETFs have disclosed their daily trades for Monday, February 10th, 2025, with notable transactions across a range of technology and biotech stocks. The largest trade of the day involved the sale of Palantir Technologies Inc (NYSE:NASDAQ:PLTR) shares, with ARK’s flagship innovation ETF, ARKK, divesting 135,775 shares for a total dollar value of $15,050,658.

In another significant move, ARK reduced its position in Roku Inc (NASDAQ:ROKU) by selling 78,654 shares, which amounted to $6,685,590. These sales may indicate a strategic shift or reallocation within ARK’s portfolios, as the investment firm is known for its active management and focus on disruptive innovation.

On the buying side, ARK’s largest acquisition was in Twist Bioscience Corp (NASDAQ:TWST), purchasing 268,210 shares through its ARKK ETF, representing a total investment of $14,027,382. This buy signals a strong conviction in the synthetic biology company, as it follows recent purchases of Twist Bioscience shares in the past week.

ARK also continued to increase its holdings in Pacific Biosciences of California Inc (NASDAQ:PACB), buying a combined 470,966 shares across the ARKK and ARKG ETFs, totaling $734,706. This move adds to ARK’s recent accumulation trend of PACB, highlighting the firm’s bullish outlook on the genomic sequencing company.

Further investments include the purchase of 100,467 shares of Illumina Inc (NASDAQ:ILMN) and 109,477 shares of PagerDuty Inc (NYSE:PD), with total dollar values of $2,085,536 for PD and an undisclosed amount for ILMN, split between the ARKK and ARKG ETFs. These trades underscore ARK’s continued interest in the genomics and digital enterprise sectors.

Additionally, ARK bought 78,752 shares of 10X Genomics Inc (NASDAQ:TXG) for a total of $1,122,216, reinforcing the fund’s focus on life sciences and biotechnology companies.

The sale of 242,350 shares of Accolade Inc (NASDAQ:ACCD) through the ARKG ETF and 492,266 shares of UiPath Inc (NYSE:PATH) across the ARKK and ARKW ETFs, with a combined dollar value of $6,872,033 for PATH, rounded out the day’s trades.

Investors following ARK’s ETFs can note the firm’s dynamic trading strategy, which often involves taking advantage of market movements to optimize the growth potential of their funds. The focus on innovative companies in genomics, artificial intelligence, and other disruptive technologies remains a hallmark of Cathie Wood’s investment philosophy.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.